Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • DPX-RSV: Phase I start

    Immunovaccine Inc. (TSX:IMV), Halifax, Nova Scotia Product: DPX-RSV Business: Infectious Molecular target: NA Description: RSV vaccine formulated with DepoVax vaccine delivery system Indication: Vaccinate against …

    Published on 1/26/2015
  • Gelesis100: Pivotal trial started

    Gelesis Inc., Boston, Mass. Product: Gelesis100 (formerly Attiva) Business: Endocrine/Metabolic Molecular target: NA Description: Superabsorbent biodegradable hydrogel that expands in the stomach to create pressure on …

    Published on 1/26/2015
  • Plecanatide: Phase III started

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: Plecanatide (formerly SP-304) Business: Gastrointestinal Molecular target: Guanylate cyclase C (GCC) (GUCY2C) Description: Guanylate cyclase C (GCC; …

    Published on 1/26/2015
  • PNT2258: Phase II started

    Marina Biotech Inc. (Pink:MRNA), Bothell, Wash. ProNAi Therapeutics Inc., Kalamazoo, Mich. Product: PNT2258 Business: Cancer Molecular target: B cell lymphoma 2 (BCL-2) (BCL2) Description: 24-base phosphodiester DNA …

    Published on 1/26/2015
  • Proellex-V telapristone: Phase IIb started

    Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Proellex-V telapristone Business: Genitourinary Molecular target: Progesterone receptor Description: Vaginally delivered selective progesterone …

    Published on 1/26/2015
  • RecAP: Phase II started

    AM-Pharma B.V., Bunnik, the Netherlands Product: RecAP (recombinant Alkaline Phosphatase) Business: Renal Molecular target: Lipopolysaccharide (LPS) Description: IV recombinant human alkaline phosphatase Indication: …

    Published on 1/26/2015
  • Sarecycline: Phase III started

    Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), Boston, Mass. Actavis plc (NYSE:ACT), Dublin, Ireland Product: Sarecycline (WC 3035) Business: Dermatology Molecular target: NA Description: Tetracycline-derived small …

    Published on 1/26/2015
  • Telapristone: Phase IIb started

    Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Telapristone (Proellex) (CDB-4124) Business: Genitourinary Molecular target: Progesterone receptor Description: Oral selective progesterone receptor …

    Published on 1/26/2015
  • TPI 287: Phase I started

    Cortice Biosciences Inc., New York, N.Y. Product: TPI 287 Business: Cancer Molecular target: Not available Description: Microtubule stabilization agent Indication: Treat brain metastases Endpoint: Maximum tolerated dose…

    Published on 1/26/2015
  • VRS-317: Phase III started

    Amunix Operating Inc., Mountain View, Calif. Versartis Inc. (NASDAQ:VSAR), Redwood City, Calif. Product: VRS-317 Business: Endocrine/Metabolic Molecular target: NA Description: Long-acting recombinant human growth …

    Published on 1/26/2015
  • 99mTc-rhAnnexin V-128: Phase I/IIa started

    Advanced Accelerator Applications S.A., Saint Genis Pouilly, France Product: 99mTc-rhAnnexin V-128 Business: Diagnostic Molecular target: NA Description: Single photon emission computed tomography (SPECT) …

    Published on 1/19/2015
  • ABBV-974: Phase I started

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABBV-974, GLPG1837 Business: Pulmonary Molecular target: Cystic fibrosis transmembrane conductance regulator…

    Published on 1/19/2015
  • AQX-1125: Phase II started

    Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Vancouver, B.C. Product: AQX-1125 Business: Dermatology Molecular target: SH2-containing inositol 5-phosphatase (SHIP) Description: SH2-containing inositol 5-phosphatase (SHIP…

    Published on 1/19/2015
  • ARC-520: Development hold

    Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Product: ARC-520 Business: Infectious Molecular target: NA Description: Short interfering RNAs targeting 2 regions of the HBV genome conjugated to N-…

    Published on 1/19/2015
  • BIND-014: Phase II started

    Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Product: BIND-014 Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Polymeric nanoparticle containing …

    Published on 1/19/2015
  • Bremelanotide: Phase III started

    Palatin Technologies Inc. (NYSE-M:PTN), Cranbury, N.J. Gedeon Richter Ltd. (Budapest:RICHTER), Budapest, Hungary Product: Bremelanotide (PT-141) Business: Genitourinary Molecular target: Melanocortin 4 receptor (MC4R) …

    Published on 1/19/2015
  • CLS-TA: Phase II started

    Clearside Biomedical Inc., Alpharetta, Ga. Product: CLS-TA, CLS-1001 Business: Ophthalmic Molecular target: Glucocorticoid receptor (GCCR) Description: Triamcinolone acetonide delivered using the companys ocular …

    Published on 1/19/2015
  • CRLX301: Phase I/IIa started

    Cerulean Pharma Inc. (NASDAQ:CERU), Cambridge, Mass. Product: CRLX301 Business: Cancer Molecular target: Tubulin Description: Nanoparticle conjugated to docetaxel Indication: Treat advanced solid tumors Endpoint: Safety…

    Published on 1/19/2015
  • EDP-788: Development discontinued

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. Product: EDP-788 Business: Infectious Molecular target: NA Description: Prodrug of EDP-322, a bicyclolide antibiotic product Indication: Treat Gram-positive …

    Published on 1/19/2015
  • GEN-003: Completed Phase II enrollment

    Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Product: GEN-003 Business: Infectious Molecular target: Infected cell polypeptide 4 (ICP4) Description: T cell …

    Published on 1/19/2015
  • Hemopurifier: Clinical trial started

    Aethlon Medical Inc. (OTCQB:AEMD), San Diego, Calif. Product: Hemopurifier Business: Infectious Molecular target: NA Description: Extracorporeal device that selectively absorbs viruses and immunosuppressive toxins from …

    Published on 1/19/2015
  • KD025: Phase II started

    Kadmon Corp. LLC, New York, N.Y. Nano Terra Inc., Brighton, Mass. Product: KD025 (formerly SLx-2119) Business: Autoimmune Molecular target: Rho-associated coiled-coil containing protein kinase 2 (ROCK2) Description: …

    Published on 1/19/2015
  • Masitinib: Phase III ongoing

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Neurology Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell …

    Published on 1/19/2015
  • Mocetinostat: Phase II started

    Mirati Therapeutics Inc. (NASDAQ:MRTX), San Diego, Calif. Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Product: Mocetinostat (MGCD0103) Business: Cancer Molecular target: Histone deacetylase (HDAC) Description: Isoform-…

    Published on 1/19/2015
  • OMP-305B83: Phase Ia started

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: OMP-305B83 Business: Cancer Molecular target: Delta-like 4 (DLL4); Vascular endothelial growth factor (VEGF) Description: Bispecific antibody …

    Published on 1/19/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993